Integrin-linked kinase as a novel molecular switch of the IL-6-NF-κB signaling loop in breast cancer

En Chi Hsu, Samuel K. Kulp, Han Li Huang, Huang Ju Tu, Min Wu Chao, Yu Chou Tseng, Ming Chen Yang, Santosh B. Salunke, Nicholas J. Sullivan, Wen Chung Chen, Jianying Zhang, Che Ming Teng, Wen Mei Fu, Duxin Sun, Max S. Wicha, Charles L. Shapiro, Ching Shih Chen

研究成果: 雜誌貢獻文章

7 引文 (Scopus)

摘要

Substantial evidence has clearly demonstrated the role of the IL-6-NF-κB signaling loop in promoting aggressive phenotypes in breast cancer. However, the exact mechanism by which this inflammatory loop is regulated remains to be defined. Here, we report that integrin-linked kinase (ILK) acts as a molecular switch for this feedback loop. Specifically, we show that IL-6 induces ILK expression via E2F1 upregulation, which, in turn, activates NF-κB signaling to facilitate IL-6 production. shRNAmediated knockdown or pharmacological inhibition of ILK disrupted this IL-6-NF-κB signaling loop, and blocked IL-6-induced cancer stem cells in vitro and estrogen-independent tumor growth in vivo. Together, these findings establish ILK as an intermediary effector of the IL-6-NF-κB feedback loop and a promising therapeutic target for breast cancer.

原文英語
頁(從 - 到)430-442
頁數13
期刊Carcinogenesis
37
發行號4
DOIs
出版狀態已發佈 - 十月 29 2015
對外發佈Yes

指紋

Interleukin-6
Breast Neoplasms
Neoplastic Stem Cells
integrin-linked kinase
Estrogens
Up-Regulation
Pharmacology
Phenotype
Growth
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Cancer Research

引用此文

Integrin-linked kinase as a novel molecular switch of the IL-6-NF-κB signaling loop in breast cancer. / Hsu, En Chi; Kulp, Samuel K.; Huang, Han Li; Tu, Huang Ju; Chao, Min Wu; Tseng, Yu Chou; Yang, Ming Chen; Salunke, Santosh B.; Sullivan, Nicholas J.; Chen, Wen Chung; Zhang, Jianying; Teng, Che Ming; Fu, Wen Mei; Sun, Duxin; Wicha, Max S.; Shapiro, Charles L.; Chen, Ching Shih.

於: Carcinogenesis, 卷 37, 編號 4, 29.10.2015, p. 430-442.

研究成果: 雜誌貢獻文章

Hsu, EC, Kulp, SK, Huang, HL, Tu, HJ, Chao, MW, Tseng, YC, Yang, MC, Salunke, SB, Sullivan, NJ, Chen, WC, Zhang, J, Teng, CM, Fu, WM, Sun, D, Wicha, MS, Shapiro, CL & Chen, CS 2015, 'Integrin-linked kinase as a novel molecular switch of the IL-6-NF-κB signaling loop in breast cancer', Carcinogenesis, 卷 37, 編號 4, 頁 430-442. https://doi.org/10.1093/carcin/bgw020
Hsu, En Chi ; Kulp, Samuel K. ; Huang, Han Li ; Tu, Huang Ju ; Chao, Min Wu ; Tseng, Yu Chou ; Yang, Ming Chen ; Salunke, Santosh B. ; Sullivan, Nicholas J. ; Chen, Wen Chung ; Zhang, Jianying ; Teng, Che Ming ; Fu, Wen Mei ; Sun, Duxin ; Wicha, Max S. ; Shapiro, Charles L. ; Chen, Ching Shih. / Integrin-linked kinase as a novel molecular switch of the IL-6-NF-κB signaling loop in breast cancer. 於: Carcinogenesis. 2015 ; 卷 37, 編號 4. 頁 430-442.
@article{96ca1b123303404190d2e177a5da9a49,
title = "Integrin-linked kinase as a novel molecular switch of the IL-6-NF-κB signaling loop in breast cancer",
abstract = "Substantial evidence has clearly demonstrated the role of the IL-6-NF-κB signaling loop in promoting aggressive phenotypes in breast cancer. However, the exact mechanism by which this inflammatory loop is regulated remains to be defined. Here, we report that integrin-linked kinase (ILK) acts as a molecular switch for this feedback loop. Specifically, we show that IL-6 induces ILK expression via E2F1 upregulation, which, in turn, activates NF-κB signaling to facilitate IL-6 production. shRNAmediated knockdown or pharmacological inhibition of ILK disrupted this IL-6-NF-κB signaling loop, and blocked IL-6-induced cancer stem cells in vitro and estrogen-independent tumor growth in vivo. Together, these findings establish ILK as an intermediary effector of the IL-6-NF-κB feedback loop and a promising therapeutic target for breast cancer.",
author = "Hsu, {En Chi} and Kulp, {Samuel K.} and Huang, {Han Li} and Tu, {Huang Ju} and Chao, {Min Wu} and Tseng, {Yu Chou} and Yang, {Ming Chen} and Salunke, {Santosh B.} and Sullivan, {Nicholas J.} and Chen, {Wen Chung} and Jianying Zhang and Teng, {Che Ming} and Fu, {Wen Mei} and Duxin Sun and Wicha, {Max S.} and Shapiro, {Charles L.} and Chen, {Ching Shih}",
year = "2015",
month = "10",
day = "29",
doi = "10.1093/carcin/bgw020",
language = "English",
volume = "37",
pages = "430--442",
journal = "Carcinogenesis",
issn = "0143-3334",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Integrin-linked kinase as a novel molecular switch of the IL-6-NF-κB signaling loop in breast cancer

AU - Hsu, En Chi

AU - Kulp, Samuel K.

AU - Huang, Han Li

AU - Tu, Huang Ju

AU - Chao, Min Wu

AU - Tseng, Yu Chou

AU - Yang, Ming Chen

AU - Salunke, Santosh B.

AU - Sullivan, Nicholas J.

AU - Chen, Wen Chung

AU - Zhang, Jianying

AU - Teng, Che Ming

AU - Fu, Wen Mei

AU - Sun, Duxin

AU - Wicha, Max S.

AU - Shapiro, Charles L.

AU - Chen, Ching Shih

PY - 2015/10/29

Y1 - 2015/10/29

N2 - Substantial evidence has clearly demonstrated the role of the IL-6-NF-κB signaling loop in promoting aggressive phenotypes in breast cancer. However, the exact mechanism by which this inflammatory loop is regulated remains to be defined. Here, we report that integrin-linked kinase (ILK) acts as a molecular switch for this feedback loop. Specifically, we show that IL-6 induces ILK expression via E2F1 upregulation, which, in turn, activates NF-κB signaling to facilitate IL-6 production. shRNAmediated knockdown or pharmacological inhibition of ILK disrupted this IL-6-NF-κB signaling loop, and blocked IL-6-induced cancer stem cells in vitro and estrogen-independent tumor growth in vivo. Together, these findings establish ILK as an intermediary effector of the IL-6-NF-κB feedback loop and a promising therapeutic target for breast cancer.

AB - Substantial evidence has clearly demonstrated the role of the IL-6-NF-κB signaling loop in promoting aggressive phenotypes in breast cancer. However, the exact mechanism by which this inflammatory loop is regulated remains to be defined. Here, we report that integrin-linked kinase (ILK) acts as a molecular switch for this feedback loop. Specifically, we show that IL-6 induces ILK expression via E2F1 upregulation, which, in turn, activates NF-κB signaling to facilitate IL-6 production. shRNAmediated knockdown or pharmacological inhibition of ILK disrupted this IL-6-NF-κB signaling loop, and blocked IL-6-induced cancer stem cells in vitro and estrogen-independent tumor growth in vivo. Together, these findings establish ILK as an intermediary effector of the IL-6-NF-κB feedback loop and a promising therapeutic target for breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=84963623538&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84963623538&partnerID=8YFLogxK

U2 - 10.1093/carcin/bgw020

DO - 10.1093/carcin/bgw020

M3 - Article

C2 - 26905583

AN - SCOPUS:84963623538

VL - 37

SP - 430

EP - 442

JO - Carcinogenesis

JF - Carcinogenesis

SN - 0143-3334

IS - 4

ER -